COVID-19 Drug Discovery Assays
Reaction Biology understands the increasingly urgent need to address the COVID-19 situation with clinically approved therapeutic drugs. To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication.
Our COVID-19 therapeutic drug testing service is available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.
We offer two assay formats designated to target SARS-CoV-2 replication. See links below.
Beside virus replication drugs are also developed to alleviate COVID-19 symptoms with a variety of targets that are well established for medical treatment:
|Target name||Target family||Assay format|
|ABL||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|AXL||Kinase||³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein|
|BRD4||Reader Domain||AlphaScreen, TSA, ITC, MST, SPR|
|BTK||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|CDK4||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|CDK6||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|EGFR||Kinase||³³PanQinase, HotSpot, NanoBRET, Cellular Phosphorylation Assay, Recombinant Protein|
|JAK1||Kinase||³³PanQinase, HotSpot, Recombinant Protein|
|JAK2||Kinase||³³PanQinase, HotSpot, Recombinant Protein|
|JAK3||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|SYK||Kinase||³³PanQinase, HotSpot, NanoBRET, Recombinant Protein|
|TYK2||Kinase||³³PanQinase, HotSpot, NanoBRET|
E Pairo-Castineira et al., Nature, 2020. Genetic mechanisms of critical illness in COVID-19.
Y Qiao et al., PNAS, 2020. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.
E Weisberg et al., Pharm Res., 2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.